ariMarketing News
Tuesday, September 26, 2023
Want Traffic?
  • Home
  • Entrepreneurship
  • Marketing
    • Digital Marketing
    • Mobile Marketing
    • Content Marketing
    • B2B Marketing
    • B2C Marketing
    • Email Marketing
    • Video Marketing
  • Social Media
  • SEO
  • AI
  • Graphic Design
  • PR
  • Videos
  • More
    • Sales Conversion
    • Website Development
    • Traffic/Lead Generation
No Result
View All Result
  • Home
  • Entrepreneurship
  • Marketing
    • Digital Marketing
    • Mobile Marketing
    • Content Marketing
    • B2B Marketing
    • B2C Marketing
    • Email Marketing
    • Video Marketing
  • Social Media
  • SEO
  • AI
  • Graphic Design
  • PR
  • Videos
  • More
    • Sales Conversion
    • Website Development
    • Traffic/Lead Generation
No Result
View All Result
ariMarketing News
No Result
View All Result
  • Marketing
  • Social Media
  • SEO
  • Entrepreneurship
  • AI
  • Graphic Design
  • Public Relations
  • Sales Conversion
  • Website Development
  • Traffic/Lead Generation
  • Videos
Home Entrepreneurship

1 Stock That’ll Make You Turn Blue in the Face for Owning

September 16, 2022
in Entrepreneurship
106 4
A A
0
21
SHARES
690
VIEWS
Share on FacebookShare on Twitter

Biotech company bluebird bio (BLUE) received FDA approval for ZYNTEGLO last month, which seems to have boosted its stock price. However, given its bleak profitability and stretched valuations, the stock might be best avoided. Read on….

bluebird bio, Inc. (BLUE) operates as a biotechnology company that researches, develops, and commercializes transformative gene therapies for severe genetic diseases.

In August, BLUE announced the U.S. Food and Drug Administration (FDA) approval for ZYNTEGLO, also known as beti-cel, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta‑thalassemia in patients who require regular red blood cell (RBC) transfusions.

Following the FDA approval, the company released details of its U.S. commercial infrastructure to support rapid access to ZYNTEGLO, which includes contract offerings and a comprehensive patient support program.

The stock has declined 38.5% over the past year and 29% year-to-date. However, it has gained 3.8% over the past month to close its last trading session at $7.09.

Here are the factors that could affect BLUE’s performance in the near term:

Stretched Valuations

In terms of its forward EV/Sales, BLUE is trading at 17.89x, 326.8% higher than the industry average of 4.19x. The stock’s forward Price/Sales multiple of 14.65 is 213.9% higher than the industry average of 4.67.

Negative Profit Margins

BLUE’s trailing-12-month ROE of a negative 87.14% compare to the industry average of a negative 38.55%. On top of it, its trailing-12-month ROTC and ROA of a negative 36.33% and a negative 103.59% are lower than their respective industry averages of a negative 21.38% and 29.73%.

Weak Past Growth Story

BLUE’s revenue has declined at a 52.4% CAGR over the past three years and a 25.6% CAGR over the past five years. Its tangible book value and total assets have decreased at CAGRs 52.3% and 34.3% over the past three years.

POWR Ratings Reflect Bleak Prospects

BLUE’s POWR Ratings reflect this bleak outlook. The stock has an overall D rating, equating to a Sell in our proprietary rating system. The POWR Ratings are calculated by considering 118 different factors, with each factor weighted to an optimal degree.

BLUE has a Sentiment grade of F in sync with Wall Street analysts’ expectations of a 3.7% downside in its stock price. The stock also has an F grade for Stability, consistent with its five-year monthly beta of 1.16.

BLUE has a D grade for Quality, consistent with its negative profitability margins.

In the 398-stock Biotech industry, it is ranked #294. The industry is rated F.

Click here to see the additional POWR Ratings for BLUE (Growth, Value, and Momentum). View all the top stocks in the Biotech industry here.

Bottom Line

The commercialization of ZYNTEGLO is expected to boost BLUE’s revenues. However, the company’s weak past revenue growth and profitability are concerning. With Wall Street analysts expecting a downturn in its stock price in the near term, BLUE might be best avoided now.

How Does bluebird bio, Inc. (BLUE) Stack Up Against Its Peers?

While BLUE has an overall POWR Rating of D, one might consider looking at its industry peers, Vertex Pharmaceuticals Incorporated (VRTX) and Biogen Inc. (BIIB), which have an overall A (Strong Buy) rating, and Genfit S.A. (GNFT) and Corcept Therapeutics Incorporated (CORT), which have an overall B (Buy) rating.


BLUE shares were trading at $6.65 per share on Friday morning, down $0.44 (-6.21%). Year-to-date, BLUE has declined -33.43%, versus a -18.35% rise in the benchmark S&P 500 index during the same period.


Anushka Dutta

Anushka is an analyst whose interest in understanding the impact of broader economic changes on financial markets motivated her to pursue a career in investment research.

More…

The post 1 Stock That’ll Make You Turn Blue in the Face for Owning appeared first on StockNews.com

Read the full article here

Tags: FinanceStocks

Subscribe to our mailing list to receives daily updates!

We won't spam you

Previous Post

Learn to Get Bigger, Better Client Leads

Next Post

Benefits vs Features | The Key to BETTER Marketing

Related Posts

Paramount, CBS launch sports creator studio ahead of Super Bowl LVIII
Entrepreneurship

Paramount, CBS launch sports creator studio ahead of Super Bowl LVIII

September 25, 2023
Green Giant taps Corn Kid’s enthusiasm for first national campaign in 7 years
Entrepreneurship

Green Giant taps Corn Kid’s enthusiasm for first national campaign in 7 years

September 20, 2023
Frito-Lay enrolls Megan Thee Stallion at Flamin’ Hot University
Entrepreneurship

Frito-Lay enrolls Megan Thee Stallion at Flamin’ Hot University

September 19, 2023
NYX turns Gen Z stars into Universal Monsters for Halloween campaign
Entrepreneurship

NYX turns Gen Z stars into Universal Monsters for Halloween campaign

September 19, 2023
Lysol debuts Air-aoke pop-up to showcase new sanitizer’s power
Entrepreneurship

Lysol debuts Air-aoke pop-up to showcase new sanitizer’s power

September 14, 2023
Over 7K Reddit communities go dark in protest over API pricing increase
Entrepreneurship

Why creator influence is primed to grow on heels of Hollywood strikes

September 14, 2023
Leave Comment

Subscribe to our mailing list to receive updates and special offers!

We will NOT span you!

Check your inbox or spam folder to confirm your subscription.

Latest Articles

10 Content Marketing Trends for Influencers in 2023

10 Content Marketing Trends for Influencers in 2023

September 26, 2023
Samsung Ads introduces new CTV ad types | MarTech

Samsung Ads introduces new CTV ad types | MarTech

September 25, 2023
Pinterest focuses on possibility in new global ad push

Pinterest focuses on possibility in new global ad push

September 25, 2023
Unlocking Brand Identity: The Core Principles

Unlocking Brand Identity: The Core Principles

September 25, 2023
Generative AI Use Cases for Marketing & Business

Generative AI Use Cases for Marketing & Business

September 25, 2023
ariMarketing News

Latest Marketing and Entrepreneurship news and articles from the most trusted sources, follow us to get the latest news and tips directly to your inbox.


Learn more

Sections

  • Artificial Intelligence
  • B2B Marketing
  • B2C Marketing
  • Content Marketing
  • Digital Marketing
  • Email Marketing
  • Entrepreneurship
  • Graphic Design
  • Mobile Marketing
  • Public Relations
  • Sales Conversion
  • SEO
  • Social Media
  • Traffic/Lead Generation
  • Uncategorized
  • Video Marketing
  • Videos
  • Website Development

Newsletter

Subscribe to our mailing list to receive updates and special offers!

We will NOT span you!

Check your inbox or spam folder to confirm your subscription.

  • Privacy
  • Terms
  • Press Release
  • Advertise
  • Contact

© 2022 ariMarketing - All rights reserved.

No Result
View All Result
  • Home
  • Entrepreneurship
  • Marketing
    • Digital Marketing
    • Mobile Marketing
    • Content Marketing
    • B2B Marketing
    • B2C Marketing
    • Email Marketing
    • Video Marketing
  • Social Media
  • SEO
  • AI
  • Graphic Design
  • PR
  • Videos
  • More
    • Sales Conversion
    • Website Development
    • Traffic/Lead Generation

© 2022 ariMarketing - All rights reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.